Data for: Speciation analysis of arsenic in urine samples from APL patients treated with single agent As2O3 by HPLC-HG-AFS
Description
Arsenic trioxide (ATO, arsenite (AsIII) in solution) has been applied successfully for treating acute promyelocytic leukemia (APL). Arsenic speciation analysis of urine is critical to reveal metabolic mechanism and the relationship between arsenic species and clinical response. The aim of the present study was to characterize arsenic species in APL urine and explore the metabolism and toxicity of arsenic in patients with APL undergoing As2O3 treatment.A simple and robust HPLC-HG-AFS method was developed and validated to quantify the levels of arsenic species (AsIII and its metabolites, monomethylarsonic acid (MMAV), dimethylarsinic acid (DMAV) and arsenate (AsV)) in urine samples from 66 APL patients. Patients received ATO at 0.16 mg/kg daily with the protocols of continuous slow-rate infusion or conventional infusion. Urine samples were collected at steady state before ATO application. AsIII and DMAV were the highest among all arsenic species in urine (p<0.0001). AsV was the lowest arsenic species in all urine samples. The relative proportions in urine were AsIII 33.00% (IQR: 24.34 to 46.82 %), DMAV 36.42 % (IQR: 25.82 to 51.98 %), MMAV 23.89 % (IQR: 19.52 % to 27.19 %) and AsV 2.22 % (IQR: 1.293 to 3.665%). Good positive correlations were found between arsenic species levels in urine and those in plasma. The AsV% treated with continuous slow-rate infusion was significantly higher than those with conventional infusion (p<0.05). Un-metabolized AsIII and DMAV were dominant arsenic compounds excreted from urine of APL patient treated ATO. MMAV and DMAV are the end products of arsenic metabolism. The levels and proportions of arsenic species possess wide variability among individual patients. Urinary arsenic can reflect the levels of arsenic in plasma. Urinary arsenic is critical as biomarker to evaluate the metabolism and toxicity of arsenic in the clinical use of ATO.